GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR EMPLOYEES UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLANGlobal Non-Qualified Share Option Agreement • August 7th, 2024 • BeiGene, Ltd. • Pharmaceutical preparations
Name of Optionee: No. of Option Shares: Ordinary Shares (as defined below) Option Exercise Price per Share: $ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average closing price of the Company’s ADSs quoted on the NASDAQ for the five trading days immediately preceding date of grant] Grant Date: Expiration Date: [No more than 10 years]
GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEIGENE, LTD.Global Restricted Share Unit Award Agreement • August 7th, 2024 • BeiGene, Ltd. • Pharmaceutical preparations
Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, including any additional terms and conditions for the Grantee’s country set forth in the appendix attached hereto (the “Appendix” and together with the Global Restricted Share Unit Award Agreement, the “Agreement”) BeiGene, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, (the “Company”) hereby grants an award of the number of Restricted Share Units listed above (an “Award”) to the Grantee named above. Each Restricted Share Unit shall relate to one ordinary share, par value US$0.0001 per share of the Company (the “Ordinary Shares”). The Ordinary Shares may be represented by American Depositary Shares (“ADSs”), and each ADS represents 13 Ordinary Shares. References herein to the issuance of Ordinary Shares shall also refer to the issuance of ADSs on the same basis of o
June 17, 2024 Aaron Rosenberg via: aaronrosenberg22@gmail.com Dear Aaron:Employment Agreement • August 7th, 2024 • BeiGene, Ltd. • Pharmaceutical preparations
This letter agreement (this “Agreement”) shall confirm the terms and conditions of your at-will employment with BeiGene USA, Inc. (“BeiGene” or the “Company”), a subsidiary of BeiGene, Ltd. We are excited about you joining our team and look forward to the addition of your professionalism and experience to help the Company achieve its goals. Your full-time start date of employment with the Company will be July 22, 2024, or a later date as mutually agreed by the Company and you.
SEPARATION AND TRANSITION AGREEMENTSeparation and Transition Agreement • August 7th, 2024 • BeiGene, Ltd. • Pharmaceutical preparations • New Jersey
This Separation and Transition Agreement (“Agreement”) is made and entered into between BeiGene USA, Inc. (“BeiGene” or the “Company”), an indirect, wholly-owned subsidiary of BeiGene, Ltd., on behalf of itself and for the benefit of its parent corporation, affiliates, subsidiaries, divisions, predecessors, and each of their past and present officers, board, agents, employees, successors, assigns, insurers, representatives, attorneys, employee benefit plans and their fiduciaries and administrators, and all other persons acting by, through, under or in concert with each of them (referred to collectively in this Agreement as “Releasees”); and Julia Wang (“you”) on behalf of yourself and your agents, heirs, executors, successors, agents and assigns. This Agreement also refers to the Company and you as the “Parties,” and to BeiGene and its parent corporation, subsidiaries and affiliates as “the BeiGene Group.” This Agreement is the “Release” that is required to be executed and not revoked
GLOBAL PERFORMANCE SHARE UNIT AWARD AGREEMENT UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLANGlobal Performance Share Unit Award Agreement • August 7th, 2024 • BeiGene, Ltd. • Pharmaceutical preparations
Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Performance Share Unit Award Agreement, including the additional performance-based vesting conditions in Appendix A and any additional terms and conditions for the Grantee’s country set forth in Appendix B attached hereto (Appendices A and B, together with the Global Performance Share Unit Award Agreement, the “Agreement”), BeiGene, Ltd., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), hereby grants an award of the number of Performance Share Units (“PSUs”) listed above (an “Award”) to the Grantee named above. Each PSU shall relate to one ordinary share, par value US$0.0001 per share of the Company (the “Ordinary Shares”). The Ordinary Shares may be represented by American Depositary Shares (“ADSs”), and each ADS represents 13 Ordinary Shares. References herein to the issuance of Ordinary Shares shall also ref
